



NDA 019943/S-032  
NDA 020011/S-039

## SUPPLEMENT APPROVAL

Abbott Laboratories  
Attention: Jean Conaway, R.Ph., R.A.C., M.B.A.  
Associate Director, Regulatory Affairs  
200 Abbott Park Road  
Abbott Park, IL 60064

Dear Ms. Conaway:

Please refer to your supplemental new drug applications (sNDAs) dated June 3, 2011, received June 3, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lupron Depot<sup>®</sup> (leuprolide acetate for depot suspension) 3.75 mg.

These prior approval supplemental new drug applications provide for revisions to the Lupron Depot 3.75 mg package insert that were requested in our May 6, 2011, Supplement Request letter and include the following changes.

1. **PRECAUTIONS** section:

**Information for Patients** subsection (item #6) - The second sentence is deleted as follows (deletion identified by a ~~striketrough~~):

The induced hypoestrogenic state **also** results in a loss in bone density over the course of treatment, some of which may not be reversible. ~~For a period up to six months, this bone loss should not be clinically significant.~~ Clinical studies show that concurrent hormonal therapy with norethindrone acetate 5 mg daily is effective in reducing loss of bone mineral density that occurs with LUPRON. (All patients received calcium supplementation with 1000 mg elemental calcium.) (See *Changes in Bone Density* section).

2. **ADVERSE REACTIONS** section:

**Changes in Bone Density** subsection - Table 4 is revised to add the 95% confidence intervals (CIs) for the mean percent change from baseline in bone mineral density of lumbar spine in women treated with Lupron alone or Lupron plus norethindrone acetate.

**Postmarketing** subsection – minor editorial/formatting changes

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert and patient package insert with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 019943  
NDA 020011  
Page 3

If you have any questions, call Karl Stiller, Regulatory Project Manager, at (301) 796-1993.

Sincerely,

*{See appended electronic signature page}*

Audrey Gassman, M.D.  
Deputy Director for Safety  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

AUDREY L GASSMAN  
06/14/2011